It is great news for Target Group, as its completely owned subsidiary, Canary RX (OTCMKTS:CBDY), receives its Health Canada sales license! Thanks to this license, the company can now manufacture and sell cannabis products directly to provincial distributors and other authorized Canadian retail supply channels.
In a joint venture partnership with Venn Cannabis, the company has been focusing on ensuring production of high-quality craft cannabis in its Simcoe, Ontario production facility. It will allow seamless delivery of its one-of-a-kind genetic offerings, while providing a robust platform for other retail brands to develop a portfolio of whole flower consumer products. The company hopes to establish itself as a leader in contract-based craft cultivation at scale within the Canadian cannabis landscape, over the next 12 to 18 months.
Tony Zarcone, CEO of Target Group & Canary RX, is delighted on achieving this crucial milestone of completing yet another licensing certification, which will pave the way ahead for their commercial strategy. With the receipt of this license, Canary RX is now in a position to execute on its future CPG strategy of providing premium grade, tactically segmented consumer brands to the market, while offering third-party processing and co-packing services on behalf of other licensed white-label partners.
